Incorporation of molecular characteristics into endometrial cancer management
暂无分享,去创建一个
[1] M. Nucci,et al. Clinicopathologic and Immunohistochemical Correlates of CTNNB1 Mutated Endometrial Endometrioid Carcinoma , 2020, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[2] M. Köbel,et al. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies , 2019, The Journal of pathology.
[3] C. Gilks,et al. Clinicopathological and molecular characterisation of ‘multiple‐classifier’ endometrial carcinomas , 2019, The Journal of pathology.
[4] C. Haie-meder,et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on adjuvant therapy , 2019, Annals of Oncology.
[5] C. Gilks,et al. Lynch syndrome screening in gynaecological cancers: results of an international survey with recommendations for uniform reporting terminology for mismatch repair immunohistochemistry results , 2019, Histopathology.
[6] Lauren L. Ritterhouse,et al. Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity , 2019, Clinical Cancer Research.
[7] Serena Wong,et al. HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy , 2019, Modern Pathology.
[8] T. Bosse,et al. Selecting Adjuvant Treatment for Endometrial Carcinoma Using Molecular Risk Factors , 2019, Current Oncology Reports.
[9] C. Genestie,et al. Reproducibility of lymphovascular space invasion (LVSI) assessment in endometrial cancer , 2019, Histopathology.
[10] A. Talhouk,et al. Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma. , 2019, Gynecologic oncology.
[11] C. Høgdall,et al. Lymph-vascular space invasion (LVSI) as a strong and independent predictor for non-locoregional recurrences in endometrial cancer: a Danish Gynecological Cancer Group Study , 2019, Journal of gynecologic oncology.
[12] E. Schmidt,et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. , 2019, The Lancet. Oncology.
[13] L. Insabato,et al. Immunohistochemical Nuclear Expression of &bgr;-Catenin as a Surrogate of CTNNB1 Exon 3 Mutation in Endometrial Cancer , 2019, American journal of clinical pathology.
[14] K. Hasegawa,et al. Impact of TP53 immunohistochemistry on the histological grading system for endometrial endometrioid carcinoma , 2019, Modern Pathology.
[15] J. Lunceford,et al. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] M. Köbel,et al. Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility , 2018, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[17] B. Job,et al. Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas , 2018, Clinical Cancer Research.
[18] Gabe S. Sonke,et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer , 2018, The New England journal of medicine.
[19] H. Putter,et al. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy , 2018, British Journal of Cancer.
[20] C. Gilks,et al. Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups , 2018, The American journal of surgical pathology.
[21] A. Talhouk,et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] J. McAlpine,et al. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses , 2018, The Journal of pathology.
[23] A. Secord,et al. Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] N. de Wind,et al. Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues , 2018, Clinical Cancer Research.
[25] H. Putter,et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial , 2018, The Lancet. Oncology.
[26] J. Goeman,et al. Blinded histopathological characterisation of POLE exonuclease domain‐mutant endometrial cancers: sheep in wolf's clothing , 2018, Histopathology.
[27] R. Soslow,et al. Molecular insights into the classification of high-grade endometrial carcinoma. , 2017, Pathology.
[28] H. Putter,et al. Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] Val Gebski,et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. , 2017, The Lancet. Oncology.
[30] Ludmila V. Danilova,et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.
[31] A. Mills,et al. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors , 2017, The American journal of surgical pathology.
[32] A. Talhouk,et al. Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancer , 2017, Cancer.
[33] G. Mills,et al. CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence , 2017, Modern Pathology.
[34] O. Dekkers,et al. Linking uterine serous carcinoma to BRCA1/2-associated cancer syndrome: A meta-analysis and case report. , 2017, European journal of cancer.
[35] P. Pollock,et al. Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition , 2016, Oncoimmunology.
[36] M. Pike,et al. Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. , 2016, JAMA oncology.
[37] D. Tritchler,et al. Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] R. Lifton,et al. Regression of Chemotherapy-Resistant Polymerase ϵ (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab , 2016, Clinical Cancer Research.
[39] H. Putter,et al. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. , 2016, The Lancet. Oncology.
[40] N. Rosenfeld,et al. Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma , 2016, The journal of pathology. Clinical research.
[41] Gyan Bhanot,et al. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. , 2016, The Journal of clinical investigation.
[42] H. Putter,et al. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts , 2016, Clinical Cancer Research.
[43] J. Ledermann,et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer , 2015, International Journal of Gynecologic Cancer.
[44] Lauren L. Ritterhouse,et al. Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. , 2015, JAMA oncology.
[45] T. Bosse,et al. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials. , 2015, European journal of cancer.
[46] A. Talhouk,et al. A clinically applicable molecular-based classification for endometrial cancers , 2015, British Journal of Cancer.
[47] P. Klenerman,et al. POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer , 2015, Clinical Cancer Research.
[48] C. Drake,et al. Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.
[49] P. Pollock,et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative , 2015, Modern Pathology.
[50] J. Xiang,et al. HER2-directed therapy: current treatment options for HER2-positive breast cancer , 2015, Breast Cancer.
[51] E. Oliva,et al. Significance of Lymphovascular Space Invasion in Uterine Serous Carcinoma: What Matters More; Extent or Presence? , 2015, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[52] D. Lambrechts,et al. Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer , 2014, Journal of the National Cancer Institute.
[53] T. Bosse,et al. L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results. , 2014, European journal of cancer.
[54] Li Ding,et al. Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. , 2014, Journal of the National Cancer Institute.
[55] A. Santin,et al. HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges. , 2014, Archives of pathology & laboratory medicine.
[56] P. Hui,et al. Marked heterogeneity of HER2/NEU gene amplification in endometrial serous carcinoma , 2013, Genes, chromosomes & cancer.
[57] P. Hui,et al. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice , 2013, Modern Pathology.
[58] C Blake Gilks,et al. Poor Interobserver Reproducibility in the Diagnosis of High-grade Endometrial Carcinoma , 2013, The American journal of surgical pathology.
[59] Steven J. M. Jones,et al. Integrated genomic characterization of endometrial carcinoma , 2013, Nature.
[60] F. Clavel-Chapelon,et al. Impact of lymphovascular space invasion on a nomogram for predicting lymph node metastasis in endometrial cancer. , 2013, Gynecologic oncology.
[61] H. Andersson,et al. External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma--a prospective randomized study. , 2012, International journal of radiation oncology, biology, physics.
[62] E. Oliva,et al. Endometrial Carcinomas: A Review Emphasizing Overlapping and Distinctive Morphological and Immunohistochemical Features , 2011, Advances in anatomic pathology.
[63] P. Zola,et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. , 2010, European journal of cancer.
[64] Yoon-Koo Kang,et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.
[65] H. Putter,et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial , 2010, The Lancet.
[66] T. Whelan,et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis , 2009, The Lancet.
[67] I. Simera,et al. Adjuvant radiotherapy for stage I endometrial cancer: systematic review and meta-analysis. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[68] H. Boezen,et al. Lymphvascular space involvement: an independent prognostic factor in endometrial cancer. , 2005, Gynecologic oncology.
[69] H. Thaler,et al. Serous Endometrial Cancers That Mimic Endometrioid Adenocarcinomas: A Clinicopathologic and Immunohistochemical Study of a Group of Problematic Cases , 2004, The American journal of surgical pathology.
[70] M. Maiman,et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study , 2004 .
[71] P. Koper,et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. , 2000 .
[72] P. Koper,et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial , 2000, The Lancet.
[73] J. Palazzo,et al. MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. , 1999, Human molecular genetics.
[74] R. Kurman,et al. WHO classification of tumours of female reproductive organs , 2014 .
[75] P. Goodfellow,et al. Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer. , 2012, Gynecologic oncology.
[76] J. Berek,et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. , 2010, Gynecologic oncology.